TETARD, Candice; MITTAINE, Marie; BUI, Stephanie; BEAUFILS, Fabien; MAUMUS, Pascale; FAYON, Michael; BURGEL, Pierre-Regis; LAMIREAU, Thierry; DELHAES, Laurence; MAS, Emmanuel; ENAUD, Raphael

doi:10.1097/MPG.0000000000002864

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

Idioma

Article de revue

Este ítem está publicado en

Journal of Pediatric Gastroenterology and Nutrition. 2020-12, vol. 71, n° 6, p. 778-781

Resumen en inglés

A chronic intestinal inflammation may occur in patients with cystic fibrosis (CF), while no therapeutic management is proposed. Although Lumacaftor/Ivacaftor is well-known to modulate the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein in lungs, no data are available on the impact of this treatment on CF intestinal disorders. We, therefore, investigated the evolution of intestinal inflammation after initiation of Lumacaftor/Ivacaftor in CF adolescents (median of follow-up: 336 days [IQR: 278;435]). Median fecal calprotectin concentrations decreased significantly after Lumacaftor/Ivacaftor initiation (102 ?g/g [IQR: 69-210]) compared with the baseline (713 ?g/g (IQR:148-852), P = 0.001). To our knowledge, this study showed for the first time that CF-related intestinal inflammation is improved by Lumacaftor/Ivacaftor treatment.< Leer menos

Metadatos

Compartir este ítem

Licencia de uso del documento

Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis

Idioma

Este ítem está publicado en

Resumen en inglés

URI

DOI

Centros de investigación